Cellicure, Inc.

Cellicure, Inc. provides innovative cell-based immunotherapy technologies, customized treatment regimens and real-world solutions for the current unmet therapeutic needs created by cancer, infectious diseases, and chronic inflammatory diseases. Our multiple groundbreaking CAR-NK technology platforms break through the current major challenges and bottlenecks of cell therapy development and industrialization, bringing significant competitive advantages. Partnering with Memorial Sloan Kettering Cancer Center (MSKCC), Cellicure’s innovative T cell engineering technology – the nCAR-T system, significantly enhances T cell infiltration and survival in tumor microenvironment, thus achieving better efficacies in the treatment of both solid tumors and hematological cancers.

Website

www.cellicure.com

External link for Cellicure, Inc.

Industrie

Biotechnology Research

Größe des Unternehmens

11-50 Mitarbeiter

Hauptsitz

Germantown, Maryland

Typ

In Privatbesitz

Gegründet

2021